Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Other financing activities (2018 - 2025)

Historic Other financing activities for Iovance Biotherapeutics (IOVA) over the last 9 years, with Q3 2025 value amounting to -$464000.0.

  • Iovance Biotherapeutics' Other financing activities rose 9260.79% to -$464000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.5 million, marking a year-over-year increase of 3841.35%. This contributed to the annual value of -$12.9 million for FY2024, which is 36003.58% down from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Other financing activities of -$464000.0 as of Q3 2025, which was up 9260.79% from -$504000.0 recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Other financing activities registered a high of -$186000.0 during Q4 2023, and its lowest value of -$6.3 million during Q3 2024.
  • Moreover, its 3-year median value for Other financing activities was -$880000.0 (2024), whereas its average is -$2.0 million.
  • As far as peak fluctuations go, Iovance Biotherapeutics' Other financing activities tumbled by 155620.05% in 2024, and later soared by 9260.79% in 2025.
  • Quarter analysis of 3 years shows Iovance Biotherapeutics' Other financing activities stood at -$186000.0 in 2023, then crashed by 373.12% to -$880000.0 in 2024, then skyrocketed by 47.27% to -$464000.0 in 2025.
  • Its last three reported values are -$464000.0 in Q3 2025, -$504000.0 for Q2 2025, and -$5.6 million during Q1 2025.